Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
11.08.2023 - Initial Clinical Data Readout from Ongoing Phase 1/2 Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Anticipated by End of 2023 Received $5 Million Research and Development Collaboration Milestone Payment from Merck Cash Runway into ...
Source: wallstreet-online.de